Phreesia Inc. Reports Q1 Fiscal 2026 Revenue Up 15% YoY; Net Loss Narrows Significantly

Reuters
05-28
Phreesia Inc. Reports Q1 Fiscal 2026 Revenue Up 15% YoY; Net Loss Narrows Significantly

Phreesia Inc. $(PHR)$ reported its financial results for the first quarter of fiscal 2026, ended April 30, 2025. The company achieved total revenue of $115.9 million, marking a 15% increase compared to the same period last year. The average number of healthcare services clients (AHSCs) rose to 4,411, up 9% year-over-year, while total revenue per AHSC increased by 6% to $26,283. Phreesia recorded a net loss of $3.9 million in the quarter, an improvement from the net loss of $19.7 million reported in the previous year. Adjusted EBITDA showed a significant increase to $20.8 million from $4.1 million in the first quarter of the prior year. The company generated $14.9 million in net cash from operating activities, compared to a net cash usage of $0.7 million in the same period last year, and achieved a free cash flow of $7.5 million, improving from negative $6.2 million. For fiscal 2026, Phreesia maintains its revenue outlook, projecting a range between $472 million and $482 million, excluding potential future acquisitions. The company has updated its Adjusted EBITDA outlook to a range of $85 million to $90 million, up from the previous range of $78 million to $88 million, citing expected improvements in operating efficiency. As of April 30, 2025, Phreesia reported cash and cash equivalents totaling $90.9 million, an increase of $6.7 million since January 31, 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Phreesia Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001412408-25-000036), on May 28, 2025, and is solely responsible for the information contained therein.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10